Patent strengthens SeekIn’s intellectual property portfolio for multi-omics, AI-powered blood-based cancer detection, recurrence monitoring, and treatment response assessment
San Diego, CA – November 18, 2026 – SeekIn Inc. (“SeekIn”), a leader in blood-based cancer early detection and monitoring technologies, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. US 12,799,537 B2, titled “Method for Predicting Cancer Risk Value Based on Multi-Omics and Multidimensional Plasma Features and Artificial Intelligence.” The patent, filed as U.S. Application No. 17/400,778, covers a proprietary approach for analyzing multiple molecular features in blood plasma using artificial intelligence to assess cancer risk and monitor disease over time.
The patented technology combines cell-free DNA (cfDNA) genomic features, protein tumor markers, and other multidimensional plasma characteristics with machine-learning algorithms to generate a cancer-risk probability. The approach incorporates features including protein tumor markers, chromosomal instability, fragment size, mitochondrial DNA, and other genomic characteristics.
Importantly, the technology is designed not only for cancer detection, but also for longitudinal monitoring of cancer recurrence and treatment response, providing a common technological foundation across multiple stages of cancer management.
“This patent represents an important foundation of SeekIn’s technology platform,” said Dr. Mao Mao, Founder and CEO of SeekIn Inc. “By combining multiple biological signals from blood with artificial intelligence, we have developed a powerful and flexible approach that can support cancer detection, recurrence monitoring, and treatment-response assessment. This technology continues to underpin our vision of making blood-based cancer testing more comprehensive and accessible.”
Why This Patent Matters
One assay, multiple clinical applications. The patented technology provides a common analytical framework spanning early cancer detection, postoperative recurrence monitoring, and treatment response assessment—the core applications addressed by SeekInCare, SeekInCure, and SeekInClarity, respectively.
Multi-omics rather than a single biomarker. By integrating genomic and protein-based signals with AI, the technology is designed to capture complementary characteristics of cancer biology and generate a more comprehensive cancer-risk assessment.
Designed for longitudinal monitoring. The patent describes analyzing samples collected at different time points to assess changes in cancer probability, providing a technological basis for monitoring recurrence and evaluating treatment response over time.
“This patent strengthens SeekIn’s intellectual property position around our core multi-omics and AI technology and supports three key applications across the cancer care continuum,” said Ms. Shujia Hao, Co-founder & CFO of SeekIn Inc. “We believe the ability to use a single blood-based technology for detection, recurrence monitoring, and treatment-response assessment represents an important advantage as we continue expanding our global cancer-testing portfolio.”
